Cellvax, founded in 2001, is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases, mainly in Cancer and Osteoarthritis (OA) fields. Cellvax is a fast-growing technology-driven preclinical service company. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products.
In addition to preclinical studies, Cellvax provide high quality consulting service in order to optimize the discovery process of candidate compounds.
Since 2007, Cellvax has successfully launched its first EUREKA project in cancer field for a total amount of 2.0 million Euros. In 2011, Cellvax has successfully obtained a 2nd FP-7 grant for a total amount of 2.4 million Euros. In October 2015, an eurostars program for the treatment of triple negative Breast cancer, and three EURONANOMED projects in 2016 in cancer and OA fields. These large European collaborative projects not only allow for Cellvax to develop its R&D activity, but also allow increasing its visibility in European countries, thus greatly beneficial for Cellvax’s development. Meanwhile, Cellvax is actively looking for partners to build up consortiums for European large collaborative projects.
In 2016, Cellvax has concluded a strong partnership with a French national organisation, BIOBANQUES, “Infrastructure BIOBANQUES-Inserm US13” inside the hospital “Hôpital de la Pitié-Salpêtrière” in Paris in order to further enhance its capacity to provide different in vivo drug validation models.
Cellvax has a strong will to collaborate with biotech companies, public and pharmaceutical laboratories which develop innovative compounds. These collaborations could be very enriching and allow to speed up the development of new drug candidates.